Important news & announcements
Network of Advanced Specialty Healthcare (NASH) Joins Transparency-Rx Coalition
Transparency-Rx, a not-for-profit coalition of transparent PBMs dedicated to changing drug pricing for the better, is thrilled to announce Network of Advanced Specialty Healthcare (NASH) as its newest member. NASH joins our growing list industry experts and stakeholders who are embarking a non-partisan effort to promote real policy changes within the healthcare industry.
NASH champions affordability and quality amid FDA’s drug importation authorization
In response to the Food and Drug Administration’s (FDA) groundbreaking decision authorizing Florida’s drug importation program, Network of Advanced Specialty Healthcare (NASH), a trailblazer in the travel-for-treatment industry, reaffirms its commitment to providing...
Agostino video rises to the top of healthcare site’s top-watched list
NASH CEO, Mike Agostino, was featured on BenefitsAlly in a video that quickly rose to the top of the site’s most-viewed list. The video is part of BenefitsAlly’s “3x3x3 Challenge,” in which leaders from the healthcare benefits industry answer three questions, using...
Insights from our blog
Setting the Record Straight: Specialty Drug Sourcing
Industry Developments Recently, NASH received a note from the payer industry regarding international sourcing compliance following a federal court case in Maryland. It is important to know that the court order and litigation are specific to certain plan sponsors and...
Bending the Cost Curve on Soaring Specialty Drug Costs
According to a recent Mercer study, the total health benefit cost per employee is projected to rise 6.5% in 2026. This is the highest increase since 2010 even after accounting for cost-reduction measures. The two leading concerns for benefit sponsors are 1) managing...
Tackling Specialty Drug Affordability: Empowering Self-Insured Employers to Regain Control Over Specialty Pharmacy Spend
The specialty drug affordability issue Prescription drug use and spend has been steadily increasing in the U.S. and around the world. In fact, less than 5% of the U.S. population requires treatment with specialty drugs, yet they account for over 50% of net drug...